ライフサイエンスコーパス: weight gain

1 of which could contribute to infertility or weight gain.

2 8; P = 0.04) were associated with postpartum weight gain.

3 greater risk of DM, likely mediated through weight gain.

4 banana as triggers were at risk of poor body weight gain.

5 weight loss or 6 months of counseling and no weight gain.

6 effect of higher efavirenz concentrations on weight gain.

7 family history, food aversion, and poor body weight gain.

8 on either appetite or adipogenesis to cause weight gain.

9 e lasting behavioural changes that attenuate weight gain.

10 etabolic rate, lower energy expenditure, and weight gain.

11 r-gestational-age, regardless of gestational weight gain.

12 gene, which is involved in the resistance to weight gain.

13 iated with obesity-related metrics and early weight gain.

14 ut mice (K2KO) exhibit increased feeding and weight gain.

15 nformative of individuals' susceptibility to weight gain.

16 rax and polycomb (ETP) gene, Asxl2, prevents weight gain.

17 n, as well as the effects of dolutegravir on weight gain.

18 upported healthy eating, PA, and appropriate weight gain.

19 errets did not lose weight but had a lack of weight gain.

20 e responsible for increased food craving and weight gain.

21 underlying this protective phenotype against weight gain.

22 otected and developed profoundly accelerated weight gain.

23 thrifty) that characterize susceptibility to weight gain.

24 daptation to OF exists and if so, attenuates weight gain.

25 ture and function with antipsychotic-induced weight gain.

26 es were associated with different amounts of weight gain.

27 d insulin resistance, even in the absence of weight gain.

28 ternal body mass index (BMI) and gestational weight gain.

29 ites, infant body composition, and postnatal weight gain.

30 apine while mitigating olanzapine-associated weight gain.

31 in drinking water (n = 8-16/group) to induce weight gain.

32 resulting in increased food intake and body weight gain.

33 given priority as this is a risk factor for weight gain.

34 leus, reduced energy expenditure, and caused weight gain.

35 ors (INSTIs) has been associated with excess weight gain.

36 associated with OLZ-induced hyperphagia and weight gain.

37 UGT1A1 genotype was not associated with weight gain.

38 bolic processes, which further contribute to weight gain.

39 ing around the potential negative effects of weight gain.

40 cient to protect mice from diet-induced body-weight gain.

41 Elevated risk was apparent even at modest weight gain.

42 the causal pathway between genetic risk and weight gain.

43 ed skin inflammation before significant body weight gain.

44 antiretroviral therapy (ART) often leads to weight gain.

45 se tissue, a process that accelerates during weight gain.

46 int was the proportion of patients with >=7% weight gain.

47 95% CI 28.6-30.3] vs 14.7% [14.2-15.3]), and weight gain (22.5%, 21.7-23.3) vs 6.9% [6.5-7.3]).

48 e/samidorphan and olanzapine groups included weight gain (24.8% and 36.2%), somnolence (21.2% and 18.

49 esulted in a statistically significant lower weight gain (37% lower weight gain compared with olanzap

50 mall-for-gestational-age infants experienced weight gain (4.3 g . kg-1 . d-1; 95% CI: 2.0, 6.5 g . kg

51 obesity exceeded the recommended gestational weight gain (58.8% vs. 31.8%, respectively).

52 In contrast, women with excess weight gain (67%) consumed 186+/-29 kcal/d more than the

53 nks/juices) was associated with 0.36 kg more weight gain (95% CI: 0.34, 0.37 kg, P < 0.001).

54 Male and female cU2 mice exhibit significant weight gain, accompanied by marked increase in abdominal

55 23 months was associated with lowest risk of weight gain (adjusted RR 0.91, 99% CI 0.87 to 0.95, p <

56 Unwanted weight gain affects some people living with HIV who are

57 Larval weight gain after 10 days of feeding on WCRMO-2 was 4-fo

58 Overall, 44.2% of participants experienced weight gain after referral, 40.8% had weight loss < 5% a

59 (N=61), CYP2B6 slow metabolizers had greater weight gain after switch (p=0.01).

60 ted with higher childhood IQ whereas greater weight gain after the first year of life was not.

61 sting glucose, prepregnancy BMI, gestational weight gain, age, parity, smoking, and history of macros

62 vidence that the interaction between sex and weight gain alters the progression of allergic asthma in

63 e dolutegravir arm, suggesting that impaired weight gain among CYP2B6 slow or intermediate metabolize

64 trations, which we hypothesized would impair weight gain among people living with human immunodeficie

65 al therapy (cART) is associated with greater weight gain among persons with HIV, though the metabolic

66 The weight gain amount associated with the lowest risk of SM

67 Weight gain analyses included 2,973 deaths (PCSM, n = 37

68 oose parvovirus infection, including reduced weight gain and 7% mortality.

69 At older ages, both deceleration of weight gain and a decrease in physical activity may refl

70 ly lower A-MeDi scores but a deceleration of weight gain and a faster decrease in physical activity.

71 genetic disruption of Bdnf and TrkB leads to weight gain and a spectrum of neurobehavioural phenotype

72 al and infant outcomes varied by gestational weight gain and across the range of prepregnancy weights

73 Weight gain and activity in an open field were unaffecte

74 rvonic acid-enriched isocaloric diet reduced weight gain and adiposity in mice fed a high fat diet.

75 n the intake of different macronutrients and weight gain and adiposity.

76 ale breeders reduced their week-on-week body weight gain and altered NR3C1 and CRH gene expression in

77 The 129P1 donor allele conferred lower body weight gain and better glucose handling during intraperi

78 se, as seen by longer survival, greater body-weight gain and better preservation of motor neurons.

79 We found that NCS have no impact on weight gain and energy balance in high fat diet induced

80 me 7, which had a synergistic effect on body weight gain and fat deposit with the znt7-null mutation.

81 HIF2alpha in the hypothalamus contributes to weight gain and glucose disorders in age-dependent manne

82 HF diet caused greater weight gain and glucose intolerance in middle-aged femal

83 1) To quantify differences in weight gain and head growth between very preterm infants

84 onths of tuberculosis treatment, and lack of weight gain and HIV independently predicted unsuccessful

85 DF11, but not rGDF8, can reduce diet-induced weight gain and improve metabolic homeostasis.

86 d diet-induced obese (DIO) mice against body weight gain and improved multiple metabolic parameters.

87 ons is necessary for protection against body weight gain and induction of UCP1 in adipose tissues ass

88 -1 receptor (CB(1) R) blockade reverses body weight gain and insulin resistance and increases energy

89 PLA2G2A protects mice on high-fat diets from weight gain and insulin resistance.

90 c polypeptide (GIP) receptor (GIPR) prevents weight gain and leads to dramatic weight loss in combina

91 M) were completely resistant to diet-induced weight gain and metabolically normal despite increased f

92 C57BL/6J-mouse dams were protected from body weight gain and NAFLD in adulthood (postnatal day (P) 11

93 AC treatment normalized HFD-induced maternal weight gain and oxidative stress, improved the maternal

94 ce displayed a severe phenotype with reduced weight gain and perinatal lethality.

95 L-27Ralpha(-/-) pups also exhibited improved weight gain and reduced morbidity.

96 no significant changes in food intake, body weight gain and relative weight of vital organs.

97 tment was associated with significantly less weight gain and smaller increases in waist circumference

98 Varying daylength also affected the weight gain and stress hormone levels.

99 Salbutamol treatment improved weight gain and survival in DOK7 myasthenic mice.

100 knockout (Lcn2KO) mice exhibited accelerated weight gain and visceral fat deposition with age, when c

101 -PL treatment to HFD dams decreased the body weight gain and WAT mass as well as lowered the serum le

102 in women with class 3 obesity, for whom low weight gain and weight loss may be associated with decre

103 hunger and satiety cues can lead to "normal" weight gain and/or "normal" weight status in children ag

104 (AEs) for Cushingoid appearance, hirsutism, weight gain, and behavior change were less for vamorolon

105 microenvironment (ATME) evolves during body-weight gain, and how these changes might influence tumou

106 D repletion stimulated appetite, normalized weight gain, and improved fat and lean mass content in C

107 ssed sleep, circadian timing, energy intake, weight gain, and insulin sensitivity during sustained in

108 e SCN restores diet-induced overconsumption, weight gain, and obesogenic symptoms.

109 nal outcome measures were glycaemic control, weight gain, and treatment failure.

110 Results show that greater rates of weight gain are associated with greater rates of lung fu

111 Low birthweight and decreased postnatal weight gain are known predictors of worse retinopathy of

112 tain ART agents differentially contribute to weight gain are unknown.

113 ither a chow or high-fat diet showed similar weight gain as the wild-type littermates.

114 samidorphan, an opioid antagonist, mitigates weight gain associated with olanzapine.

115 e the upper limit of interquartile range for weight gain at 1 year.

116 mic-specific ablation of Fgf13 recapitulated weight gain at 30 degrees C.

117 In a clinical trials cohort, we studied weight gain at 48 weeks among treatment-naive participan

118 In an observational cohort, we studied weight gain at 48 weeks following switch from efavirenz-

119 not during the other diets predicted greater weight gain at both 6 and 12 months.

120 weight and proportion of patients with >=10% weight gain at week 24.

121 (N=462), CYP2B6 slow metabolizers had lesser weight gain at week 48 among participants receiving efav

122 underscore the importance of avoiding excess weight gain before middle age for preventing this highly

123 underscore the importance of avoiding excess weight gain before middle age for preventing this highly

124 f added sugar was associated with postpartum weight gain (beta: 0.05; 95% CI: 0.004, 0.10; P = 0.05).

125 5% CI [2.54-25.93], p-value 0.007), maternal weight gain between 20 and 27 weeks <p10 (RR(adj) 2.04,

126 he formation of hepatic lipid droplets, body weight gain, blood glucose, and improved serum biochemic

127 f maternal pre-pregnancy BMI and gestational weight gain, both in clinical categories and across thei

128 nutrition education and food supplements for weight gain but not for increase in CD4+ T cells.

129 tritional education and food supplements for weight gain, but not for increase in CD4+ T cells.

130 at inhibition of BSH activity should enhance weight gain by altering the BA pool, host signalling and

131 lation of risk factors such as hypertension, weight gain, cigarette smoking, and loss of cardiorespir

132 HFD induced increased body weight gain, circulating levels of leptin, cholesterol,

133 E-cigarette vaping also caused slower weight gain compared to mice exposed to room air.

134 eding increased body temperature and reduced weight gain compared with continuous feeding, an effect

135 lly significant lower weight gain (37% lower weight gain compared with olanzapine plus placebo).

136 We measured growth rates (weight gain), coral color (a proxy for Symbiodiniaceae d

137 al a drug to improve appetite and/or improve weight gain, currently available pharmacologic intervent

138 -individual variability in susceptibility to weight gain despite an equally obesogenic environment in

139 es and food intake but exhibit resistance to weight gain despite living in the modern world's obesoge

140 some cases failed to demonstrate significant weight gain despite nutritional supplementation.

141 sed self-reported grand-maternal gestational weight gain, diet, physical activity, and smoking during

142 In this study, we investigated whether weight gain differs among treatment-naive PLWH starting

143 Results remained significant when weight gain during follow-up was adjusted for.

144 s a "thriftier" metabolic phenotype prone to weight gain during overfeeding and resistant to weight l

145 a modest U-shaped relation between maternal weight gain during pregnancy and premenopausal breast ca

146 Adequate weight gain during pregnancy is important to both matern

147 ight status before pregnancy, in addition to weight gain during pregnancy.

148 mong women who do not lose their gestational weight gain during the postpartum period.

149 t energy intake requirements for recommended weight gain during the second and third trimesters were

150 The effect of excessive gestational weight gain (EGWG) is related to adverse health outcomes

151 duction performance by reducing feed intake, weight gain, farrowing rate, and litter size.

152 kg/m2 at switch were associated with greater weight gain following switch among women; age >=60 was t

153 zed two cohorts to study pharmacogenetics of weight gain following switch from efavirenz- to INSTI-ba

154 re were no changes in mean body weight, body weight gain, food consumption or food efficiency for mal

155 The median percent weight gain for all recipients at 1 year posttransplant

156 self-report of maternal BMI and gestational weight gain for some of the cohorts, and the potential o

157 by 1.53 (95% CI: 0.14; 2.92) points] whereas weight gain from 12 mo to 5 y was not associated with IQ

158 Rapid weight gain from age 1 year to 4 years, defined as an in

159 Weight gain from baseline (mean +/- SD age: 31 +/- 9 d)

160 Mean weight gain from baseline to 12 months was 1.8 kg (95% C

161 The primary outcome was daily weight gain from enrollment up until the age of 17 wk (a

162 rain energy use is inversely related to body weight gain from infancy until puberty.

163 ted the impact of fluid overload (defined by weight gain > 5%) or positive cumulative fluid balance o

164 group compared with the olanzapine group had weight gain >=10% (17.8% and 29.8%, respectively; number

165 ed to treat [NNT]=7.29; odds ratio=0.50) and weight gain >=7% (27.5% and 42.7%, respectively; NNT=6.2

166 Postdiagnosis weight gain (> 5% of body weight), compared with stable

167 In women with obesity, excess gestational weight gain (>=270 g/week) occurs in two out of three pr

168 who adhere to the 2009 Institute of Medicine weight-gain guidelines.

169 adherence to the 2009 Institute of Medicine weight-gain guidelines.

170 the association between maternal gestational weight gain (GWG) and preterm birth according to pre-pre

171 led longitudinal studies, having gestational weight gain (GWG) as an example.

172 y (SMM), but the contribution of gestational weight gain (GWG) is not well understood.

173 l protein during pregnancy for a gestational weight gain (GWG) of 12 kg (recalculated from a GWG of 1

174 the impact of PPDS on inadequate gestational weight gain (GWG) or small for gestational age (SGA) in

175 Gestational weight gain (GWG), maternal clinical chemistry, maternal

176 shown their efficacy in reducing gestational weight gain (GWG); however, their applicability in routi

177 Both low and high gestational weight gain have been associated with adverse maternal a

178 (-/-) mice were not protected against excess weight gain, hepatic steatosis or glucose intolerance, t

179 rgy intake/expenditure balance (hyperphagia, weight gain, hypersomnia, fatigue, and leaden paralysis)

180 risk for sequelae of a sedentary lifestyle: weight gain, hypertension, hyperlipidaemia, insulin resi

181 We performed a pooled analysis of weight gain in 8 randomized controlled clinical trials o

182 rtility, early growth retardation, excessive weight gain in adulthood, heterotaxia, pre-axial polydac

183 variables were independently associated with weight gain in all participants: baseline CD4 count, bas

184 investigated the interaction between sex and weight gain in an experimental model of lung allergic in

185 ibution of obesity-associated microbiotas to weight gain in animal models, microbiota resilience may

186 E2 attenuated weight gain in both genotypes.

187 r, low birth weight had a negative impact on weight gain in both groups.

188 Overexpression of NRG4 reduced weight gain in diet-induced obese mice, while overexpres

189 rtially responsible for muGIPR-Ab to prevent weight gain in DIO mice, demonstrating a role of adipocy

190 I), and the risk of obesity, overweight, and weight gain in French adults, with a prospective design.

191 Weight gain in infancy was associated with IQ [per z-sco

192 seen with greater size at birth and greater weight gain in infancy.

193 ated and resulted in improvements in LCI and weight gain in infants with CF.

194 y weight, we found that the decrease in body weight gain in mice treated with metformin is not direct

195 y associated with AP-induced hyperphagia and weight gain in mice.

196 tes olanzapine (OLZ)-induced hyperphagia and weight gain in mice.

197 onnectivity correlated with the magnitude of weight gain in patients, and these effects multiplied wh

198 romote peripheral and central adipose tissue/weight gain in people with human immunodeficiency virus

199 2B6 metaboliser genotype was associated with weight gain in PLWH starting efavirenz-based ART.

200 Metformin prevented weight gain in response to a high-fat diet in wild-type

201 GEN-exposed mice exhibited reduced uterine weight gain in response to E2 treatment or artificial de

202 We sought to explore factors associated with weight gain in several randomized comparative clinical t

203 , and persons >=60 years experienced greater weight gain in the 2 years after versus before switch.

204 -glycemic diets were associated with greater weight gain in the first 6 mo postpartum.

205 ination with a high-fat diet led to enhanced weight gain in the presence of male or female gonads.

206 Recent studies have reported weight gain in virologically suppressed persons living w

207 IT, they express great concern, and unwanted weight gain in young people can be prevented by age-appr

208 ly increased food intake and caused dramatic weight gain, in agreement with published data; however,

209 ductions at 6 and 12 months in interdialytic weight gain, in extracellular fluid volume, and in plasm

210 baseline demographic factors associated with weight gain including lower CD4 cell count, higher HIV t

211 Yearly weight gain increased following switch to INSTIs, partic

212 The risk of poor body weight gain increased in FPIES triggered by cow's milk (

213 CTR in POMC neurons leads to increased body weight gain, increased adiposity, and glucose intoleranc

214 AK2 deficiency reduced high-fat-diet-induced weight gain, increased energy expenditure and ameliorate

215 acute HFOF can identify individuals prone to weight gain, indicating that an individual's capacity to

216 with hyperphagia and accelerated postweaning weight gain induced by a high-carbohydrate diet (hiCHO).

217 CBC reduced body weight gain, inflammation, hepatic steatosis, hyperglyce

218 Data suggest that weight gain is associated with a decrease in responsivit

219 ses in waist circumference suggest that this weight gain is associated with an increase in fat mass.

220 Emerging data suggest that weight gain is associated with changes in neural respons

221 We investigated whether weight gain is associated with neural changes in respons

222 Weight gain is commonly seen in lung transplant (LTx) re

223 Weight gain is ubiquitous in clinical trials of ART init

224 no changes to maternal food intake, maternal weight gain, litter size, or gestational length.

225 coccus lactis subspecies (subsp) cremoris on weight gain, liver fat, serum cholesterol, and insulin r

226 ichment, resulted in significant increase in weight gain, lowered risks for injuries and death, and r

227 The Fatp2 (-/-) mice had reduced weight gain, lowered serum triglyceride, and increased s

228 regnancy (OR(adj) 2.72, 95% CI [2.28-3.24]), weight gain < 5 kg (OR(adj) 2.37, 95% CI [1.99-2.83]), s

229 While some of this weight gain may be an appropriate return-to-health effec

230 possibly higher PCSM, and that postdiagnosis weight gain may be associated with a higher mortality as

231 Maternal obesity and excessive gestational weight gain may have persistent effects on offspring fat

232 elated disease, mitigate secondary causes of weight gain (medications, sleep deprivation), and solici

233 Interestingly, no weight gain, no extrapyramidal disorder except rare akat

234 g pregnancy defined by no excess gestational weight gain, no smoking, a healthy diet and being physic

235 Excess caloric intake is linked to weight gain, obesity, and related diseases, including ty

236 ate metabolizers could explain the increased weight gain on dolutegravir compared with efavirenz obse

237 hibit decreased food intake, protection from weight gain on standard and high-fat diets, and an adipo

238 We compared effects of PCB-77 on weight gain or loss and glucose homeostasis in male vs.

239 diet index was associated with 0.04 kg less weight gain over 4-y periods (95% CI: 0.05, 0.02 kg; P <

240 tea/coffee) was associated with 0.68 kg less weight gain over 4-y periods (95% CI: 0.69, 0.66 kg; P <

241 ate functional connectivity at baseline, and weight gain over the course of 12 weeks of antipsychotic

242 d ruminal acidosis showed significantly less weight gain over the course of the experiment, in additi

243 Therefore, the individual predisposition to weight gain over time can be assessed by 24-h overfeedin

244 troviral regimens and the trajectory of this weight gain over time, especially among women, require f

245 fed a chow diet presented with blunted body-weight gain over time, had lower fat mass, and were more

246 2B6 metaboliser genotype was associated with weight gain (P = .009), with extensive metabolizers gain

247 therapy, CYP2B6 genotype was associated with weight gain, possibly reflecting withdrawal of the inhib

248 Maternal body mass index and gestational weight gain predict future obesity status of the offspri

249 s associated with AP-induced hyperphagia and weight gain provide candidate biomarkers and mechanistic

250 d paternal overweight, excessive gestational weight gain, raised fasting plasma glucose during pregna

251 Optimal gestational weight gain ranges were estimated for each prepregnancy

252 Weight gain rate per week, obesity and diastolic blood p

253 previous studies have limited their focus to weight gain, rather than growth in length/height or body

254 l-2,3-dehydro-2-deoxyneuraminic acid inhibit weight gain, reduce steatosis, and decrease adipose tiss

255 and infant outcomes, but optimal gestational weight gain remains uncertain and not well defined for a

256 kl mice exhibiting lower plasma Pi, improved weight gain, restored plasma and renal alphaKlotho level

257 Weight gain results from an increase in energy intake wi

258 Additionally, all of the gestational weight gain scenarios (inadequate, recommended, or exces

259 sceral and hepatic adiposity associated with weight gain since participants were 21 years old varied

260 es in children from birth to 24 mo and child weight gain, size, and body composition.

261 ound significantly better (p < 0.05) growth, weight gain, specific growth rate, and best (but not sig

262 1.944, P = 0.041).In the highest gestational weight gain strata, especially the third-trimester, the

263 Dolutegravir is associated with more weight gain than efavirenz.

264 NNRTIs, rilpivirine was associated with more weight gain than efavirenz.

265 egravir and bictegravir associated with more weight gain than elvitegravir/cobicistat.

266 egravir and bictegravir associated with more weight gain than elvitegravir/cobicistat.

267 nhibitors (INSTIs) were associated with more weight gain than protease inhibitors or non-nucleoside r

268 nofovir alafenamide was associated with more weight gain than tenofovir disoproxil fumarate, abacavir

269 nt groups consistently displayed higher body weight gain than the untreated chicks.

270 Children in program 4 had higher weight gain than those in programs 1, 2, and 3 at all ti

271 nsfer inhibitor use was associated with more weight gain than were protease inhibitors or nonnucleosi

272 tegory by selecting the range of gestational weight gain that was associated with lower risk for any

273 Central SIRT1 is required for MCH-induced weight gain through its actions on the sympathetic nervo

274 in many different systems, from post-dieting weight gain to circadian rhythms.

275 Whereas previous studies linked this weight gain to disturbed endocrine parameters after slee

276 ed linear mixed models to compute individual weight gain trajectories.

277 domised trial testing the non-inferiority of weight gain velocity of children with SAM receiving (a)

278 r two complementary conditions of restricted weight gain: vertical sleeve gastrectomy (VSG) or food r

279 offspring to perinatal penicillin, inducing weight gain via microbiota disturbance.

280 Mean gestational weight gain was 13.7 kg (SD = 6.9 kg).

281 The mid-trimester weight gain was 2.7 kg and 8.0 kg in the second and the

282 Weight gain was greater in more recent trials and with t

283 Weight gain was greater in women than men.

284 At all examined study time points, weight gain was highest among PLWH starting dolutegravir

285 dy mass index (kg/m2) was <20 or gestational weight gain was less than recommendations.

286 Weight gain was not related to demographics, activity, m

287 Weight gain was seen across all treatment groups in both

288 Maternal gestational weight gain was self-reported in 2007, and breast densit

289 Weight gain was similar between CYP2B6 extensive metabol

290 Weight gain was similar in CYP2B6 extensive metabolizers

291 Mean weight gain was substantial (7.1 kg [SD 7.4] in the teno

292 ad, and glycemic index have been linked with weight gain, whereas fiber may protect against obesity.

293 cles the experience of the author with acute weight gain while overfeeding, in the context of current

294 breast cancer risk, likely mediated by less weight gain with a DRRD; however, independently of weigh

295 us (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretrovira

296 t that reduced BRD7 levels lead to increased weight gain with little effect on glucose metabolism.

297 associations of maternal BMI and gestational weight gain with the risk of overweight/obesity througho

298 MN decreased energy expenditure and promoted weight gain without altering blood glucose levels, silen

299 ve suggested associations between INSTIs and weight gain, women living with HIV (WLHIV) have been und

300 toxification-related genes, food collection, weight gain, worker and male numbers, and production of